PT  - JOURNAL ARTICLE
AU  - Marioni, Gino
AU  - Ottaviano, Giancarlo
AU  - Marchese-Ragona, Rosario
AU  - Fasanaro, Elena
AU  - Tealdo, Giulia
AU  - Zanotti, Claudia
AU  - Randon, Benedetto
AU  - Giacomelli, Luciano
AU  - Stellini, Edoardo
AU  - Blandamura, Stella
TI  - Nuclear survivin expression correlates with endoglin-assessed microvascularisation in laryngeal carcinoma
AID  - 10.1136/jclinpath-2016-204230
DP  - 2017 Dec 01
TA  - Journal of Clinical Pathology
PG  - 1033--1037
VI  - 70
IP  - 12
4099  - http://jcp.bmj.com/content/70/12/1033.short
4100  - http://jcp.bmj.com/content/70/12/1033.full
SO  - J Clin Pathol2017 Dec 01; 70
AB  - Aims Survivin—a member of the family of inhibitor of apoptosis proteins that control cell division, apoptosis and metastasis—is overexpressed in virtually all human cancers, including laryngeal squamous cell carcinoma (LSCC). Recent findings also correlate survivin expression with the regulation of angiogenesis. The novel main aim of this study was a preliminary investigation into the potential role of survivin expression in LSCC neoangiogenesis, as determined by endoglin-assessed microvascular density (MVD).Methods Immunohistochemical expression of nuclear survivin and endoglin-assessed MVD were ascertained by image analysis in 75 consecutive LSCCs.Results Statistical analysis disclosed a strong direct correlation between nuclear survivin expression and MVD. Patients whose nuclear survivin expression was ≥6.0% had a significantly higher LSCC recurrence rate, and a significantly shorter disease-free survival (DFS) than those with a nuclear survivin expression <6.0%. The LSCC recurrence rate was also higher and the DFS shorter in patients with endoglin-assessed MVD ≥6.89%. The OR for recurrence was 2.79 in patients with LSCC with a nuclear survivin expression ≥6.0%, and 12.31 in those with an MVD≥6.89%.Conclusions Survivin-targeting strategies to enhance tumour cell response to apoptosis and inhibit tumour growth should receive more attention with a view to developing agents for use in multimodality advanced LSCC treatment, or combined with conventional chemotherapy. Given the present preliminary evidence in LSCC, survivin targeting should also be further investigated for anti-angiogenic purposes, to reduce tumour blood flow and induce cancer necrosis.